Relay Therapeutics (RLAY)
US Market

Relay Therapeutics (RLAY) Income Statement


Relay Therapeutics Income Statement

Last quarter (Q1 2023), Relay Therapeutics's total revenue was $226.00K, a decrease of -46.06% from the same quarter last year. In Q1, Relay Therapeutics's net income was $-94.24M. See Relay Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 1.19M$ 1.38M$ 3.03M$ 82.65M$ 0.00$ 0.00
Cost of Revenue
Gross Profit
$ 226.00K-----
Operating Expense
$ 143.19M$ 312.33M$ 230.04M$ 138.45M$ 84.05M$ 49.89M
Operating Income
$ -344.81M$ -310.95M$ -227.01M$ -55.80M$ -84.05M$ -49.89M
Net Non Operating Interest Income Expense
$ 15.03M$ 8.79M$ 830.00K$ 3.40M$ 8.80M$ 1.11M
Other Income Expense
$ 7.09M$ 11.66M$ -137.69M$ -16.00K$ -58.00K$ -9.00K
Pretax Income
$ -322.70M$ -290.51M$ -363.87M$ -52.41M$ -75.31M$ -48.78M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -322.70M$ -290.51M$ -363.87M$ -230.20M$ -75.31M$ -48.78M
Basic EPS
$ -2.81$ -2.59$ -3.82$ -5.40$ -1.15$ -0.75
Diluted EPS
$ -2.81$ -2.59$ -3.82$ -5.40$ -1.15$ -0.75
Basic Average Shares
$ 461.93M$ 112.23M$ 95.14M$ 42.62M$ 65.43M$ 65.43M
Diluted Average Shares
$ 340.61M$ 112.23M$ 95.14M$ 42.62M$ 65.43M$ 65.43M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 143.19M$ 312.33M$ 230.04M$ 138.45M$ 84.05M$ 49.89M
Net Income From Continuing And Discontinued Operation
$ -322.70M$ -290.51M$ -363.87M$ -52.41M$ -75.31M$ -48.78M
Normalized Income
$ -235.54M$ -302.19M$ -226.18M$ -52.41M$ -75.31M$ -48.78M
Interest Expense
$ -344.82M$ -310.95M$ -227.01M$ -55.80M$ -84.05M$ -49.89M
$ -342.48M$ -306.82M$ -223.08M$ -52.25M$ -81.20M$ -47.73M
Currency in USD

Relay Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis